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1. Introduction 
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease of 
unknown etiology. The prevalence of SLE is worldwide from 4 to 250 per 100,000. Statistics 
demonstrate that lupus is somewhat more frequent in Africans, Americans and people of 
Chinese and Japanese descent. It is a disease with predominance of the female sex, the ratio 
among SLE sufferers is about 9:1.  
It is often discovered in their childbearing years. It affects heterogeneity multiple organs of 
the body and presents aberrant immunological findings and especially the presence of 
antinuclear antibodies. The clinical course and prognosis is unpredictable and may be 
characterized by periods of remissions and chronic or acute relapses. The mortality rate 
among patients with SLE is at least three times that of the general population. (Aberer, 2010; 
Ng & Chan, 2007; Ramírez, 2007) 
2. Etiopathogenesis 
The etiopathogenesis that causes lupus is not known. Interactions between susceptibility 
genes and environmental factors result in abnormal immune responses. The antigens, 
autoantibodies, and immune complexes persist for prolonged periods of time, allowing 
inflammation and contribute to irreversible tissue damage developing the disease.  
The SLE is a multigenic disease. In most genetically susceptible individuals, if enough 
variations accumulate multiple genes they contribute to abnormal immune responses and 
disease results. Some genes influence clinical manifestations of disease in various ethnic 
groups. (Javierre & Richardson, 2011; Koike, 2011)  
The SLE is more frequent in female sex. The females make higher antibody responses than 
the males. The estrogens favour a prolonged immune response increasing the risk of 
developing SLE. 
Several environmental stimuli may influence in the development of the SLE. Exposure to 
ultraviolet light causes skin injures in approximately 70% of SLE patients. Some 
infections, for example Epstein-Barr virus (EBV), induce abnormal immune response. 
Occasionally, some drugs stimulate the immune system and can induce SLE. The extreme 
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3. Clinical manifestations 
The illness impacts in the patients with SLE, in three aspects: physical, psychological and 
social. (Ng & Chan, 2007; Ramírez, 2007) 
3.1 Physical manifestations 
The physical manifestations varies between different patients, and in a single patient the 
disease activity varies presenting exacerbations interspersed with periods of relative 
quiescence. SLE may involve one or several organ systems, but it is not usual for all systems 
to be affected simultaneously, and the severity varies from mild and intermittent to 
fulminant.  
The general symptoms, particularly fatigue and fever, are present most of the time. The 
myalgias and or arthralgias are common. Most patients have intermittent polyarthritis most 
frequently in hands, wrists, and knees. The exercise capacity and muscular strength are 
reduced in these people. 
Lupus dermatitis can be “butterfly” rash on the face, discoid lupus, photosensitivity, 
systemic rash, urticaria. About one-third of the patients have small, painful ulcerations on 
the oral or nasal mucosa. 
The nephropathy in SLE varies from mild proteinuria and microscopical hematuria to end-
stage renal failure.  
The neuropsychiatric symptoms can be caused by a diffuse process or vascular occlusive 
disease. The manifestations of diffuse CNS lupus are cognitive dysfunction, depression and 
headache, myelopathy, peripheral neuropathy, seizures and psychosis. Many patients get a 
thromboembolic or haemorrhagic complication of the brain. 
The pulmonary manifestations of SLE are pleuritis, acute pneumonitis and chronic 
fibrotising alveolitis. 
The cardiac manifestations are pericarditis, myocarditis, fibrinous endocarditis of Libman-
Sacks, heart failure, arrhythmia and myocardial infarctions. 
The hematologic manifestations of SLE are anemia, usually normochromic normocytic, 
hemolysis, leukopenia lymphopenia, and thrombocytopenia. 
The gastrointestinal manifestations are nausea, sometimes with vomiting, diarrhea or 
diffuse abdominal pain caused by peritonitis, intestinal vasculitis. 
The ocular manifestations are sicca syndrome, nonspecific conjunctivitis, retinal vasculitis 
and optic neuritis. 
Women with SLE have more risk of first and second trimester foetal losses and of premature 
birth. (Nakashima et al, 2011; Ng & Chan, 2007; Ramírez, 2007) 
3.2 Psychological manifestations 
Many persons with SLE experience high levels of emotional distress. The depression is the 
most common psychological symptom and the anxiety is another feeling quite frequently 
experienced. 
The links between physical symptoms and psychological wellbeing have been studied in 
SLE relatively little research. 
Studies have revealed that the physical symptoms from SLE affect psychologically to people 
which suffer.  
The skin abnormalities and photosensitivity, disfiguring skin lesions and pleuritic pain are 
associated with depression, poor self-esteem and poor social functioning.  
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The sufferings from greater organ damage, such as the kidneys, experience greater 
psychological distress.  
The disease-related changes to the direct central nervous system can result in depression or 
anxiety in SLE patients. 
Levels of daily stress among patients with SLE are generally higher than those experienced 
by the general population. Such stress could cause depression and anxiety producing the 
worsening of physical and mental function in these people. (Ng & Chan, 2007; Ramírez, 
2007; Zakeri et al, 2011). 
The pharmacology treatment of physical symptoms of SLE can also contribute to feelings of 
desperation and helplessness among sufferers. The side effects of steroids, such as a “moon 
face” and weight gain have an additional negative impact on self-esteem. (Navarrete-
Navarrete et al, 2010; Ng & Chan, 2007; Chaiamnuay et al, 2007) 
The persons with SLE often have worries about their illness, their treatment plans, the level 
of pain caused by the illness, and the occurrence of the next “flare-up”. These people often 
have a sense of helplessness that the illness is not yet curable even after appropriate 
treatment is adopted. These worries can be deleterious to their health and self-esteem. The 
researches associate abnormal illness-related behaviours, helplessness with increased levels 
of fatigue. (Burgos et al, 2009; Chuang et al, 2010; Ng & Chan,2007) 
Few studies have pointed out that psychiatric symptomatology has been correlated 
significantly with family and social support. (Ng & Chan, 2007) 
3.3 Social manifestations 
The uncertainty of SLE affects the social life of these people. 
Chronic fatigue and joint pains make it impossible for many with SLE to perform to the 
level expected by themselves and others. This loss of the ability to meet “normal” standards 
of performance can be very depressing.  
Coupled with the side effects of drug treatment, this condition can lead to feelings of shame, 
isolation and worthlessness. To avoid the feeling of rejection, many may isolate themselves 
and refrain from interacting with friends and even family members.  
The illness can also have an effect on major life decisions such as career development, 
wedding and pregnancy plans.  
Some may have deep-seated fears of desertion and rejection by spouse and friends.  
All these social problems are salient and tend to contribute to emotional and social 
disturbances (Baker & Pope, 2009; Ng & Chan, 2007) 
4. Diagnosis 
The integral diagnosis in the patients with SLE include the aspects: physical, psychological 
and social. 
4.1 Physical diagnosis 
4.1.1 Clinic and laboratory 
The laboratory tests serve to establish the physical diagnosis, to follow the course of disease, 
and to identify adverse effects of therapies. These might include hemoglobin levels, platelet 
and leukocyte counts, erythrocyte sedimentation rate, urinalysis, and serum levels of 
creatinine or albumin, ANA, antibodies to double-stranded DNA (dsDNA), antibodies to 
Sm, antibodies antiphospholipid, anti-Ro, polyclonal gammaglobulinaemia, complement  
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Criterion Definition
1. Malar Rash Fixed erythema flat or raised, over the malar eminences, 
tending to spare the nasolabial folds
2. Discoid rash Erythematous raised patches with adherent keratotic 
scaling and follicular plugging; atrophic scarring may 
occur in older lesion
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by 
patient history or physician observation
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, 
observed by physician
5. Nonerosive Arthritis Involving 2 or more peripheral joints characterized by 
tenderness, swelling, or effusion
6. Pleuritis or Pericarditis 1 Pleuritis – convincing history of pleuritic pain or rubbing 
heard by a physician or evidence of pleural effusion 
1. OR  
2. Pericarditis – documented by electrocardiogram or rub 
or evidence of pericardial effusion
7. Renal Disorder 1. Persistent proteinuria > 0.5 grams per day or > than 3+ if 
quantitation not peformed 
1. OR 
2. Cellular casts –may be red cell, hemoglobin, granular, 
tubular, or mixed
8. Neurologic Disorder 1. Seizures – in the absence of offending drugs or known 
metabolic derangements; e.g., uremia, ketoacidosis, or 
electrolyte imbalance 
1.OR 
2. Psychosis – in the absence of offending drugs or known 
metabolic derangements, e.g., uremia, ketoacidosis, or 
electrolyte imbalance
9. Hematologic Disorder 1 Hemolytic anemia – with reticulocytosis
1. OR 
2. Leukopenia -- < 4,000/mm3 on ≥ 2 occasions 
1. OR 
3. Lyphopenia --< 1,500/mm3 on ≥ 2 occaions 
1. OR 
4. Thrombocytopenia --< 100,000/mm3 in the absence of 
offending drugs 
10. Immulogic Disorder 1. Anti- DNA: antibody to native DNA in abnormal titer 
1. OR 
2. Anti-Sm: presence of antibody to Sm nuclear antigen 
1. OR 
3. Positive finding of antiphospholipid anibodies on: 
1.1-an abnormal serum level of IgG or anticardiolipin 
antibodies 
2.2. a positive test result for lupus anticoagulant using a 
standard method, or  
3.3.a false-positive test result for at least 6 months 
confimed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test 
11. Positive Antinuclear Antibody An abnormal titer of antinuclear antibody by 
immunofluorescence or an equivalent assay at any point in 
time an in the absence of drugs
Table 1. 1997 Update of the 1982 American College of Rheumatology Revised Criteria for 
Classification of Systemic Lupus Erythematosus Criterion. 
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values (C3 and C4), IFN-inducible genes, soluble IL-2, and urinary adiponectin or monocyte 
chemotactic protein 1. 
In the diagnosis of SLE there is no single symptom or finding that is sufficient in itself, it is 
based on the clinical and the laboratory and on the American Rheumatism Association 
(ARA) classification criteria. Any combination of 4 of 11 criteria makes it likely that the 
patient has SLE. See TABLE 1.  
Antinuclear antibodies (ANA) are positive in more 98% of patients during the course of 
disease; repeated negative tests suggest that the diagnosis is not SLE. The antibodies to 
double-stranded DNA and antibodies to the Sm antigen, specific for SLE, with compatible 
clinical favor the diagnosis. The presence in an individual of multiple autoantibodies 
without clinical symptoms should not be considered diagnostic for SLE, although such 
persons are at increased risk since clinical SLE begins in most patients years after 
autoantibodies appear.(Nakashima et al, 2011) 
4.1.2 Disease activity and damage caused by SLE 
4.1.2.1 Disease activity 
The disease activity indices have been created at standardizing the SLE activity assessment. 
Some of such indices are: European Consensus Lupus Activity Measurement (ECLAM), 
Lupus Activity Index (LAI), British Isles Lupus Assessment Group (BILAG), Lupus 
symptom inventory (LSI) and Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI).  
The ECLAM assesses disease activity over the last month, and comprises 15 clinical and 
laboratory parameters. Its scores ranges are from 0 to 10. (Griffiths et al, 2005) 
The LAI comprises four scores to assess clinical activity: physician’s global evaluation, 
opinion of the doctor about disease severity, laboratory findings and immunosuppressive 
treatment. Its scores ranges are from 0 to 3. (Griffiths et al, 2005) 
The BILAG index measures SLE disease activity. It is composed of eight organ-based 
systems: general symptoms, mucocutaneous, respiratory, cardiovascular, neurological, 
musculoskeletal, renal and hematological. It is represented with alphabetical letters 
depending of the clinical characteristics present and their behavior during one month. 
BILAG “A” represents the presence of one or more severe SLE characteristics. BILAG “B” 
indicates more moderate characteristics of the disease. BILAG “C” includes mild 
symptomatic characteristics. BILAG “D” represents the previous activity. BILAG “E” 
indicates that a system has never been involved. (Isenberg et al, 2005) 
The LSI measures clinical activity in the last month. It includes five main symptoms: flares, 
headaches, joint inflammation, muscles and weakness. Its score ranges are from 1 to 5. The 
higher score is the symptoms with more severity (Duvdevany et al, 2011) 
The SLEDAI assesses disease activity in the previous ten days. It evaluates the organ 
affected, clinical and laboratory parameters. The scores greater than 8 indicates active 
disease. A three-point variation between medical visits indicates disease activation, and 
variations greater than or equal to 12 points mean severe activity. It was reviewed in the 
year 2000, originating SLEDAI-2K. The modifications included the persistence of rash, 
mucosal ulcers, alopecia, and proteinuria greater than 0.5 in 24h and had ability to 
differentiate clearly active patients from inactive ones or those with minimum activity. 
(Freire al, 2011) 
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4.1.2.2 Damage caused by SLE 
The damage indices in organ-based systems can be used as a health measure in patients 
with chronic diseases. The damage caused by SLE has reference a symptom present at least 
six months that develops in tissue damage which produces irreversible organ damage. It 
detects damages in patients which can have resulted from disease activity or treatment or 
comorbidities. 
The ACR published the Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology - Damage Index (SLICC/ACR-DI), in 1996. This instrument 
approaches 12 organ-based systems. The damages caused by SLE affect to patients who 
result in physical or/and mental disabilities, worsening the patient’s quality of life, which is 
an important indicator of the health status of patients with chronic diseases. (Freire al, 2011) 
4.2 Psychological and social diagnosis 
The committee on Outcome Measures in Rheumatology Clinical Trials (OMERACT) of the 
ACR has recognized the importance of measure function and wellbeing from the patient’s 
view as a criterion to determine clinical improvement.  
The psychological and social diagnosis can be obtain through data collection via a semi-
structured interview performed by the same physician and measured about the illness 
perception of the own patient, experienced thought and behavior by chronic illness, the role 
of personality and coping with stressful life situations and social relationships. (Freire et al, 
2011; Ramírez, 2007) 
4.2.1 Illness perception 
The model proposes by Leventhal support that self-regulatory patients are active problem-
solvers who seek to make sense of illness and form illness perceptions that influence coping 
strategies.  
These representations of illness are composed of cognitions about the name of the illness 
and its associated symptoms, timeline, causes, personal control and understanding, 
effectiveness of its treatment. These disease perceptions determine how individuals respond 
to illness in their emotions, behavior, health care, expectations, attitude to the illness, 
coping, functioning and cooperation with health professionals. (Kaptein & Broadbent, 2007; 
Nowicka-Sauer, 2007) 
The methods used to assess illness perception are verbal and nonverbal tools. Among 
nonverbal are: Pictorial Representation of Illness and Self-Measure (PRISM) and drawing. 
Among verbal are the Brief-Illness Perception Questionnaire (B-IPQ). (Broadbent et al, 2006; 
Nowicka-Sauer, 2007). 
Pictorial representation of illness and self-measure 
Büchi et al have developed the Pictorial Representation of Illness and Self-Measure (PRISM). 
It is a measure of the “burden of suffering” due to illness from the patient's perspective that 
includes factors directly related to the disease, disease-related intrusion in relevant aspects 
of life, like family, work or friendship.  
The burden of suffering is a subjective experience arising out of or identified by means of 
one´s awareness of his own states or processes, even clinician with great experience derived 
from direct observation (facial expression, body posture, signs of sorrow, etc) are unable to 
detect the inner feelings of their patient. PRISM is a measure, by simplicity of use, that is 
easily understood by patients and widely accepted by them.  
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A red disk , 5cm in diameter with magnet on the underside were given to the patient , this 
disk represents his/her illness and the patient is also presented with a metal board which 
has a fixed yellow disk 7cm in diameter at the bottom right hand corner, this yellow disk 
represents the patient “self”. The patient is then asked “where in your life (board) would 
you put the (illness) disk at the moment?” The distance between the two disks, representing 
Illness and Self respectively, is inversely related to the burden of the illness. This distance, 
measured is called the Self- Illness Separation (SIS). The possible range of SIS is 0±27 cm.  
PRISM can be used in people with SLE in everyday clinical practice as a quantitative 
assessment instrument of patient-focussed health. (Buchi et al, 1998; Buchi et al, 2000) 
Drawing 
The drawings allow to assess patients views on how are the heterogeneity of clinical 
presentations, variety of illness perception, understanding and experiences of the SLE 
patients. This method help to talk, it makes the patients open up to their emotions, views, 
and experiences. It improves understanding of these patients in a short amount of time. 
Together with questionnaire assessment, the drawings can be an important source of 
information on how the illness can be experienced and felt and how it influences patients 
emotions and behaviors. (Daleboudt et al, 2011; Nowicka-Sauer, 2007) 
Brief-Illness Perception Questionnaire (B-IPQ) 
The B-IPQ contains eight items to score on a scale from 0 to 10 and one open-ended question 
where the participants have to state the three most important causes for their disease. A 
mean score is calculated for every scale and the reported causes can be grouped into 
categories on the basis of common themes. The B-IPQ has been shown to be a valid and 
reliable measure to assess illness perceptions in ill populations, but no validation for 
patients with SLE has been done. (Broadbent et al, 2006). 
4.2.2 Cognitive-behavioral analysis 
The experience of chronic illness, one like SLE, could become for the patient the focus of all 
its daily attention, decreasing the time devoted to family, friends, work, or developing as a 
person. The ill could focus his time on trying to control or avoid his disease with its 
emotions, sensations, memories, or thoughts producing human suffering that restrict 
healthy behavior. 
There are measures widely used for clinical outcomes, that assess human sufferers produced 
by chronic illness. These are: Beck Depression Inventory (BDI), Pain Anxiety Symptoms 
Scale (PASS), Sickness Impact Profile (SIP), Chronic Pain Acceptance Questionnaire (CPAQ), 
Mindful Attention Awareness Scale (MAAS), Chronic Pain Values Inventory (CPVI). 
Beck Depression Inventory 
The Beck Depression Inventory (BDI) is a measure of depression and general emotional 
distress. It has 21 items. Each scored goes from zero (neutral) to three (maximum severity). 
The BDI range is from zero to sixty three. The twenty is a cutoff for clinically significant 
symptoms. (Beck et al, 1988; McCracken et al, 2007) 
Pain Anxiety Symptoms Scale 
The Pain Anxiety Symptoms Scale (PASS) is a measure of anxiety responses and avoidance 
related to chronic pain. The original version is a 40-item measure. Patients indicate the 
frequency of anxiety from zero (never) to five (always). The total score ranges from zero to 
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two hundred. The PASS includes subscales: cognitive anxiety symptoms, escape and 
avoidance, fearful thinking and physiological anxiety responses.  
The PASS-20 is a new version of PASS-40. It is a 20-item measure. It assesses of fear, 
avoidance, cognitive, and anxiety responses related to chronic pain. The rate each item goes 
from zero (never) to five (always) indicating how the patients do or experience each of the 
actions or thoughts described. (McCracken et al, 2004; McCracken & Yang, 2006; McCracken 
et al, 2007; Roelofs et al, 2004) 
Sickness Impact Profile 
The Sickness Impact Profile (SIP) is used to assess physical and psychosocial disability on 
daily functioning. It is a 136-item measure. It has three domains (physical, psychosocial 
and other aspects of disability) and twelve categories of daily functioning. The categories 
can be scored separately or combined with domains. The categories in the physical 
domain are ambulation, mobility, body care and movement. The categories in the 
psychosocial domain include social interaction, alertness behavior and emotional 
behavior. The categories in the other domain are sleep and rest, eating, home 
management, recreation and pastimes, work and communication. The patients, when 
answering the SIP, endorse statements that describe problems in relation to their health. 
All scores range from 0 to 1. Higher scores indicate greater disability. (McCracken & 
Yang, 2006; McCracken et al, 2007) 
Chronic Pain Acceptance Questionnaire 
The Chronic Pain Acceptance Questionnaire (CPAQ) is a measure of acceptance of chronic 
pain. It is a 20-item inventory. Each item has a scale of zero (never true) to six (always true). 
The total score ranges from zero to one hundred and twenty. It has two subscales: activity 
engagement (eleven items) and pain willingness (nine items). The activity engagement 
measures tendency to perform usual daily activities regardless of pain present. The pain 
willingness measures the relative absence of attempts to control or avoid pain present. 
(McCracken et al, 2004; McCracken & Yang, 2006; McCracken et al, 2007) 
Mindful Attention Awareness Scale 
The Mindful Attention Awareness Scale (MAAS) is a measure of mindfulness. It is a 15-item 
inventory. Each item is rated on a scale from one (almost always) to six (almost never). The 
items content reflects the opposite of mindfulness or mindlessness. The items of the lower 
frequency are taken to represent a higher level of mindfulness. The items greater than eighty 
correlate with measures of emotional distress and physical symptoms. (Brown and Ryan, 
2003; McCracken et al, 2007) 
Chronic Pain Values Inventory 
The Chronic Pain Values Inventory (CPVI) is based on the acceptance and commitment 
therapy. It assesses two scores: success and the discrepancy between importance and 
success in six domains of patient values. The first set considers the values and rates the 
importance of these patients in each domain. The second set rates how these persons have 
lived according to their values in each domain. The values domains are: family, intimate 
relations, friends, work, health, and growth or learning. The rates of each item go from zero 
(not at all important/successful) to five (extremely important/successful). Low success in 
living in accord with an unimportant value produces less suffering than low success living 
in accord with important value. (McCracken & Yang, 2006) 
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4.2.3 Personality and coping variables 
The capacities of patient to cope with stress to go off defence mechanisms that result in the 
psychological response to determine as these persons are living with the SLE. (Eriksson & 
Lindstrom, 2005) 
4.2.3.1 Defence mechanisms 
The defence mechanisms are defined by American Psychiatric Association as “automatic 
psychological processes that protect the individual against anxiety and from the awareness 
of internal or external dangers and stressors, mediating the individual’s reactions to 
emotional conflicts and to internal or external stressors”. (American Psychiatric Association. 
Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 1994) 
The Defence Style Questionnaire (DSQ-88) estimate behaviour indicating four defence 
styles: namely maladaptive action, image-distorting, self-sacrificing and adaptive styles. 
The Hostility and Direction of Hostility Questionnaire (HDHQ) provides a measure of 
hostility that reflects an attitudinal personality trait and shows the participant’s reaction to 
frustrating occurrences. These questionnaires have been used with rheumatic patients. (Bai 
et al, 2009; Hyphantis et al,2006; Hyphantis, 2010) 
4.2.3.2 Sense of coherence 
The sense of coherence (SOC) introduced by Antonovsky, is defined as “a global life 
orientation that expresses the extent to which one has a pervasive, enduring though 
dynamic sense of confidence that the stimuli deriving from one’s internal and external 
environments in the course of living are structural, predictable, and explicable; the resources 
are available to one to meet the demands posed by the stimuli; and these demands are 
worthy of investment and engagement”.  
The SOC scale assesses the three dimensions: comprehensibility, manageability, and 
meaningfulness. It is an instrument measuring of global orientation how people manage 
stressful situations, not to measure each of the three core components separately.  
In patients with SLE, have been found correlations between SOC scores and physical and 
psychological quality of life components. The use of SOC scale detect those patients who are 
coping poorly with the illness because they have poor psychological resources, in order to 
promote psychotherapeutic interventions that improve patients’ QOL. (Abu-Shakra et al, 
2006; Hyphantis et al, 2011) 
4.2.4 Quality of life 
The quality of life (QOL) has been defined by WHO as “individuals perceptions of their 
position in life in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns”. (WHOQOL Group, 1995) 
As health-related QOL scales are measures centered on the patient’s opinion. It assessments 
the patient’s health status throughout the disease and their satisfaction with treatment. 
These instruments are very used because these persons are the most interested in their own 
outcome. (Freire et al, 2011) 
The instruments for QOL assessment can be self-administered or interview-administered. It 
can be generic or specific for a certain disease. Some generic instruments are the WHOQOL 
and Short Form 36-item Health Survey Questionnaire (SF-36). Other specific instruments are 
Systemic Lupus Erythematosus Symptom Checklist (SSC), Systemic Lupus Erythematosus 
Quality of Life Questionnaire (SLEQOL), Systemic Lupus Erythematosus Needs 
Questionnaire (SLENQ), Lupus Quality of Life (LupusQOL) 
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WHOQOL 
The World Health Organization (WHO) has developed an international quality of life 
assessment. This measure shows physical, psychological and social well-being of patients 
connecting with the WHO’s definition of quality of life. In clinical practice, the WHOQOL 
assessments help clinicians to discover the areas in which a patient is most affected by 
disease, and to decide about treatment. 
The WHOQOL exists in twenty nine languages, contain hundred questions group by 
domains and sub-domains of quality of life. These are: I Physical Capacity (1 Pain and 
discomfort, 2 Energy and fatigue, 3 Sleep and rest), II Psychological (4 Positive feelings, 5 
Thinking, learning, memory and concentration, 6 Self-esteem, 7 Bodily image and 
appearance, 8 Negative feelings), III Level of Independence (9 Mobility, 10 Activities of daily 
living, 11 Dependence on medication or treatments, 12 Work capacity), IV Social 
Relationships (13 Personal relationships, 14 Social support, 15 Sexual activity), V 
Environment (16 Physical safety and security, 17 Home environment, 18 Financial resources, 
19 Health and social care: accessibility and quality, 20 Opportunities for acquiring new 
information and skills, 21 Participation in and opportunities for recreation/ leisure 
activities, 22 Physical environment (pollution/noise/traffic/climate), 23 Transport), VI 
Spirituality/Religion/ Personal Beliefs. (WHOQOL Group, 1995). 
Short Form 36-item Health Survey Questionnaire 
The Short Form 36-item Health Survey Questionnaire (SF-36) is a generic instrument for 
QOL assessment. It is a questionnaire with thirty-six items, grouped into the eight domains, 
which are: physical function, role limitations due to physical health, pain, general health 
perception, vitality, social function, role limitations due to emotional problems, and mental 
health. It summarize the results in two areas: physical and psychological. The score ranges 
are from zero to hundred and are directly proportional to the state of health.. There are 
validation studies in SLE patients, in a variety of socio-cultural contexts using many 
languages SF-36 versions. The SF-36 was recommended as the instrument of choice for 
measuring HRQOL in SLE. (Freire el al, 2011; Thumboo & Strand, 2007)  
Systemic Lupus Erythematosus Symptom Checklist 
The Systemic Lupus Erythematosus Symptom Checklist (SSC) measure the impact of the 
disease and its treatment on the individual. This questionnaire study 38 symptoms in a four-
point scale, where zero is the best health status and four, the worst. (Freire et el, 2011; 
Sanchez et al, 2009; Thumboo & Strand, 2007) 
Systemic Lupus Erythematosus Quality of Life Questionnaire 
The Systemic Lupus Erythematosus Quality of Life Questionnaire (SLEQOL) has 40 items 
into the six domains: physical function, occupational activity, symptoms, treatment, mood 
and self-image. The scores vary from one to seven, and the lower (fourty) the score is the 
best the QOL and the higher (two hundred and eighty) the score is the worse QOL. This 
questionnaire showed to have more sensitivity to changes over time than SF-36. (Freire et el, 
2011; Sanchez et al, 2009; Thumboo & Strand, 2007) 
Systemic Lupus Erythematosus Needs Questionnaire 
The Systemic Lupus Erythematosus Needs Questionnaire (SLENQ) has seven domains: that 
assess the following needs: psychological-spiritual-existential, health services, health 
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information, physical, social support, daily living, and employment. This questionnaire 
showed moderate correlations with SF-36. (Moses et al, 2007; Freire et el, 2011). 
Lupus Quality of Life 
The Lupus Quality of Life (LupusQOL) contains thirty four items in eight domains: physical 
health, emotional health, body image, pain, planning, fatigue, intimate relationships and 
burden to others. (Freire et el, 2011; McElhone et al, 2007; Sanchez et al, 2009; Thumboo & 
Strand, 2007) 
Cross-sectional studies and prospective studies have identified the age, the duration, the 
activity and damage disease, some specific manifestations of SLE as fatigue, pain or end-
stage renal failure, the corticosteroids or cytotoxic, the knowledge of lupus, the illness 
related behaviours, the educational status, the self-efficacy, the learned helplessness, the 
ability to work, the home environment and the social support as factors associated may 
influence health-related quality of life (HRQOL) in SLE patients. (McElhone K et al, 2006; 
Navarrete-Navarrete et al, 2010; Thumboo & Strand, 2007)  
5. Treatment 
The SLE is no curable and complete remissions are rare, sometimes is cyclical and 
sometimes is progressive, is heterogeneous in manifestations and has significant mortality 
risk. It is a disease that requires lifelong treatment. 
SLE may have a higher impact on patients’ life than other chronic illnesses, and the level of 
impact may be influenced by type of treatment. SLE is a disease that can significantly impact 
physiological, psychological and social functioning, influencing in health-related quality of 
life of the patients. The pharmacologic and non-pharmacologic therapies may have an 
additive or synergistic effect on improving on these patients HRQOL (Daleboudt et al, 2011; 
Thumboo & Strand, 2007). 
5.1 Patient-centred care 
The treatment of SLE’s people should be patient-centred ensuring that the patients are 
treated with dignity and respect. Good communication between doctors and patients is 
essential. These ills and their families and carers need a high-quality communication, 
supported by evidence-based information that provides treatment and care based on best 
practice. Patients should have the opportunity to be involved in the decisions about their 
treatment and care. The physician should take into account needs and preferences of the 
patients. Families and carers should have the information and support they need. 
Information, treatment and care should be given at patients, families and carers by 
culturally appropriate written information tailored to their needs. (Michalski & Kodner , 
2010; van der Giesen et al, 2007; Villanueva, 2009) 
5.2 Multidisciplinary treatment 
SLE is a complex disease. Healthcare professionals of these patients must pay careful 
attention to all items of illness (physical, psychological, family and social) in 
multidisciplinary cooperation. It is the most frequent that patient comes at primary care 
physicians. The American College of Rheumatology Ad Hoc Committee on SLE guidelines 
recommends that primary care physicians should refer SLE patients to rheumatologists to 
establish SLE definitive diagnosis, activity and severity disease and treatment of general 
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disease and some medication side effects. Rheumatologists should work with a 
multidisciplinary team allowing coordinated care of patient. This includes family 
physicians, other specialist physicians, psychotherapies, rehabilitations, nurses and social 
workers. Family Medicine is a specialty focused person-centred care. Competent and 
polyvalent family physicians may be allowed to attend the patient in his/her whole life. 
From primary care should monitored ill a long time and treated when presents other 
pathologies or some medication side effects (infection, cardiovascular disease, osteoporosis,) 
or mild symptom SLE. From other specialist physicians should treat damaged major organ. 
From psychotherapy should teach coping strategies to favor psychosocial adjustment. 
(Aberer, 2010; Beckerman et al, 2011; Michalski & Kodner , 2010; Ramírez, 2007; Taylor & 
McMurray, 2011; van der Giesen et al, 2007; Villanueva, 2009) 
5.3 Physical treatment 
Medical treatment and a recommended lifestyle are necessary for optimal functioning in life 
SLE patients. 
The pharmacological treatment is always individual. It depends if it is to control acute, 
severe flares or to develop maintenance strategies that suppress symptoms and prevent 
organ damage. This therapy also depends on adverse effects of medications, whether 
disease manifestations are life-threatening or to cause organ damage, whether 
manifestations are potentially reversible and the best approaches to preventing 
complications of disease. (Michalski & Kodner , 2010; Taylor & McMurray, 2011; Yildirim-
Torner C & Diamond B, 2011.) 
The most important drugs are: nonsteroidal anti-inflammatory drugs, hydroxychloroquine 
corticosteroids, immunosuppressive drugs (azathioprine, cyclophosphamide, methotrexate, 
mycophenolate). Almost all patients should take hydroxychloroquine and most 
corticosteroids with immunosuppressive drugs. With better management, patients with 
lupus live longer but are at increased risk of disease and treatment-related complications, 
including infection, cardiovascular disease, and osteoporosis. (Michalski & Kodner , 2010; 
Taylor & McMurray, 2011; Yildiri-Toruner C & Diamond B, 2011.) 
Pharmacologic and biologic therapies reducing disease activity and/or levels of anti-dsDNA 
antibodies improving HRQOL for SLE patients.(Thumboo & Strand, 2007; Dall'era & 
Chakravarty, 2011) 
The damages disease in skin or alopecia can be improved with treatment of these lesions 
and/or use of cosmetics to camouflage these lesions.  
The use of a highly protective broad-spectrum (UVB and UVA) sunscreen can effectively 
prevent skin photosensitive lesions in patients’s SLE. (Kuhn et al, 2011; Obermoser & Zelger 
B, 2008 ; Thumboo & Strand, 2007) 
5.4 Psychological and social treatment 
The psychotherapy programs should help to equip the SLE’s patients with knowledge and 
skills of coping for managing the illness and to build up familiar and social support. 
The patients with rheumatic illness experience significant restrictions into their daily life. 
There are researches that prove that the cognitive behavioral therapy (coping methods and 
contextual methods) improves on these persons their experience of physical symptom (pain, 
fatigue), daily activity, psychology and social functioning.  
Although there are few researches on SLE’s patients, the cognitive behavioral therapy (CBT) 
(coping methods and contextual methods) reaches above average levels in physical 
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functioning, psychic functioning and social functioning obtaining a significant improvement 
in the HRQOL, independent of the activity level of the disease. (McCracken & Vowles, 2008; 
Navarrete-Navarrete et al, 2010; Ramírez, 2007) 
5.4.1 Psychotherapy methods 
The behavioral therapy is in a state of development. Actually, there are three generations. 
They are based on chosen strategies the two firsts direct change, coping methods, and the 
third indirect change, contextual methods. The coping methods are focused on control or 
change in the content of psychological experiences and the contextual methods include 
acceptance, mindfulness and values. These therapies are characterized: the first by 
behavioral change, the second by cognitive models and the third by processes of acceptance 
and values-based action. They are integrative and not exclusive, they encompass each other. 
In these therapies the problems are rationalized and contextualized and the sensations 
produced by them can improve experience and acceptance. 
The psychotherapy that use coping methods includes: understanding SLE providing 
information, understanding one’s rights as a patient, controlling pain and fatigue oneself, 
teaching stress management through concept of stress and relaxation techniques 
(diaphragm breathing and deep muscle relaxation), alternative thought control strategies 
that help to manage frustration and emotion (self-instructional training and thought 
stopping), humour and optimism as coping strategies, cognitive restructuring (identifying 
and discussing the consequences of main errors in thinking, main core beliefs, challenging 
thoughts), demonstrating problem-solving skills, developing personal strengths, training in 
social skills (assertiveness techniques, how to say no without feeling bad, asking another 
person to change their behavior) locating community resources for rehabilitation. 
(Navarrete-Navarrete et al, 2010; Ng P & Chan, 2007; Ramírez, 2007; Robles-Ortega & 
Peralta-Ramírez, 2006; Sheldon,1995) 
The psychotherapy that includes contextual methods is acceptance and commitment 
therapy (ACT) and mindfulness.  
The ACT centers on building positive and flexible behavior patterns rather than removing 
symptoms carrying up processes of acceptance, contact with the present moment and 
values-based action. This model includes: acceptance, cognitive defusion, contact with the 
present moment, self-as-context, values and committed action (Hayes et al, 2006). The 
studies with this treatment on patient’s rheumatic illness are very up to date. (McCracken & 
Vowles, 2008) 
Mindfulness is a technique and a component of the acceptance and commitment therapy. It 
can be understood as attention, awareness and reflection of present moment non-
judgmental. This model include: nonconceptual, focused on the present, non-judgmental, 
intentional, participatory observation, emotional, exploratory and liberating. The researches 
with this technique on patient’s rheumatic are also very up to date. (Germer et al, 2005) 
5.4.2 Psychotherapy in SLE 
The patients with SLE live with fears about the illness because they have nothing or little 
knowledge about the clinic, treatment and prognosis of the illness. The researches have 
shown that to improve the understanding of these persons with accurate information of the 
mechanisms of SLE contribute to a better adjustment to live with their illness because their 
negative beliefs about it are reduced influencing on their self-esteem. (Ng P & Chan, 2007) 
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5.4.2.1 Chronic pain 
The chronic pain is a great suffering for SLE’s patient.  
The medical and surgical treatments may produce variable results and adverse events and 
iatrogenic complications on any patient with chronic pain. The use of other means for pain 
reduction, as the programs of physical activity may reduce pain improving HRQOL in these 
ills. 
The subjective nature of pain makes complicated this problem. The pain is a response to 
nociception on the patient influenced by genetic, personal history, physiologic state and 
psychological and social context. And the pain influences on physical, psychological and 
social functioning. 
The patients with chronic pain may be influenced by distressing thoughts and emotions and 
ineffective behaviors focusing on their pain. The increasing attempts to control pain may be 
associated with increasing the limits of their functioning interfering with healthy living. An 
alternative approach, are personal’s choice of adaptive responses adjusted to chronic pain. 
The research has shown the utility of ACT. The experienced pain, with control, allows more 
healthy activities.  
The acceptance-oriented responses to chronic pain may improve physical (disability), 
psychological (suffering) and social (working) functioning over time. The positive purposes 
of families and friends, with more patient attitude about behavior pattern, may make easier 
the processes of acceptance. 
The mindfulness-based treatment methods are addressed to these patients suffering chronic 
pain. The mindfulness is based: present-focused, realistic contact with pain, neutral 
awareness of pain, change experience pain and effective behavioral. Mindfulness is 
observation and commitment. The researches show mindfulness may get better well-being 
of patients with chronic pain. It gives them more realistic experiences and more effective 
flexible behavioral. (McCracken et al, 2007; Thumboo & Strand, 2007) 
5.4.2.2 Fatigue 
Fatigue is lack of energy, physical and mental tiredness. On SLE’s patients, it compromises 
quality of life, reducing psychological well-being, because these difficulties on daily 
activities affect personal and social life.  
Fatigue is present on many chronic ills, for example: multiple sclerosis, cancer, chronic 
fatigue syndrome, rheumatoid arthritis, SLE.  
The physiopathology of fatigue in SLE have been difficult to identify but likely to be multi-
factorial. 
Fatigue may be associated with SLE disease process and with pain, lack of physical exertion, 
sleep disturbance, depression, anxiety, stressful life events, infection, medication side effects 
and characteristics of the local environment (lighting and temperature). (Bakshi 2003; 
Dittner et al, 2004 ; Godaert et al, 2002 ; Neill, 2005 ; Zifko, 2004).  
Researches for reducing fatigue in people with SLE are few and show strategies not 
completely effective in the long-term. The treatment of chronic illnesses fatigue usually 
combines pharmacological and nonpharmacological therapy. Pharmacological therapy 
efficacy is questioned in fatigue of SLE’s patients and nonpharmacological therapy is 
essential for her management. This therapy include exercise, rehabilitation programmes and 
cognitive behavioral therapy. (Godaert et al, 2002) 
Studies suggest aerobic exercise is effective for reducing fatigue in some people with SLE. 
This exercise includes low-impact aerobics, walking, cycling, and jogging. It should be 
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appropriate for each ill and take into account individual fluctuations in fatigue intensity, if 
feasible, it might be executed home-based or in supervised classes. This exercise should 
begin early in the disease course or following the disease, start with low intensity activities 
and avoid provoking symptoms, gradually increasing in intensity, duration and frequency, 
combine aerobic and resistance training where possible. It is recommended to carry out 
between fifteen and thirty minutes at least three times weekly if it is tolerated. This exercise 
type appears to be effective in reducing fatigue in patient with cancer and chronic fatigue 
syndrome. (Mancuso et al, 2010; Stricker et al. 2004 ; Watson & Mock, 2004).  
Fatigue is a variable and subjective experience that may decline inactive life-style 
disproportionally affecting physical activity, psychological and societal participation. In this 
case, it might be required to promote interventions of self-management of fatigue and better 
illness cognitions and coping styles by means of CBT. 
Cognitive behavioural therapy helps to identify and to challenge perpetuating factors. These 
are: insufficient coping with the disease and dysfunctional cognitions about fatigue such as 
lack of control and catastrophizing (negative thoughts are put into reality perspective), 
deregulation of sleep (to adhere biologic rhythm and to fixed bedtimes and wake-up times 
during the day), deregulation of activity (a base level activity and alternating rest and 
activity should be established), low social interactions (to favor realistic expectations toward 
the participation in social relations). 
Studies show that cognitive behavioural therapy with/without exercise is effective in 
reducing fatigue in chronic fatigue syndrome, multiple sclerosis, cancer-related fatigue and 
SLE because it improves self-efficacy, increasing their quality of life. (Edmonds et al, 2004; 
Navarrete-Navarrete et al, 2010; Neill et al, 2006; Wagner & Cella, 2004)  
5.4.2.3 Neuropsychiatric manifestations 
Cognitive dysfunction, anxiety and depression are frequent in patient’s SLE. The 
consequences of SLE living may impact personal life, including interpersonal relationships 
and professional rol. The majority of SLE patients present depression and emotional 
distress. These affective disturbances are very rarely attributed to disease activity alone, and 
may influence psychosocial factors. Cognitive dysfunction may coexists with psychiatric 
disorders. Their association in SLE is not clear. Some study shows the psychological state of 
the ill may influence self-reporting of cognitive problems (Farrin et al, 2003; Kozora et al, 
2006; Kozora et al, 2007; Nowicka-Sauer et al, 2011; Panopalis et al, 2007; Vogel et al, 2011; 
Zakeri et al, 2011.) 
Neuropsychiatric manifestations should be diagnosed and treated in these patients first as if 
they had not SLE, and secondarily as if they had it. (Bertsias et al, 2010) 
Clinical guideline about care of patients with depression and a chronic physical health 
problem recommend physical activity programme and cognitive behavioural therapy. 
(NICE, 2009) 
Cognitive behavioural therapy sets up role cognitive representations or perceptions and 
emotional responses of patient’s SLE that can influence individual’s ability to manage his 
illness by selecting coping strategies. The ill may organize an individual’s response around 
five cognitives. These include: representation of their illness, perceived duration, 
unpredictability, control, perceived of severity and cause. There are researches that show 
better depressive symptoms and cognitive dysfunction in patient SLE following cognitive 
behavioural therapy.(Bertsias & Boumpas, 2010 ; Bertsias et al, 2010; Greco et al, 2004; Philip 
et al, 2009) 
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6. Conclusion 
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease of 
unknown etiology, with predominance of the female sex in their childbearing years.  
SLE affects heterogeneity multiple organs of the body and presents aberrant immunological 
findings. The clinical course and prognosis is unpredictable. It can affect socio-
psychologically to patients experiencing high levels of emotional distress by affecting 
physical, pharmacology treatment, their own worries about illness, abnormal illness-related 
behaviours and affecting social life. 
The integral diagnosis in the patients with SLE include the aspects: physical, psychological 
and social. The physical diagnosis of SLE is based on the clinical and the laboratory and on 
the American Rheumatism Association (ARA) classification criteria. The psychological and 
social diagnosis can be obtain through data collection via a semi-structured interview 
performed by the same physician and measure about the illness perception of the own 
patient, experienced thought and behavior by chronic illness, the role of personality and 
coping with stressful life situations and social relationships.  
The integral treatment of patient’s SLE include pharmacological and non-pharmacological 
therapies that may have an additive or synergistic effect on these patients. These treatment 
should be patient-centred favouring high-quality communication between doctors and 
patients with their families and carers supported by evidence-based information that 
provides treatment and care based on best practice. These patients should be treatment by 
multidisciplinary team that include family physicians, rheumatologists, other specialist 
physicians, psychotherapies, rehabilitations, nurses and social workers. Pharmacological 
treatment and recommended lifestyle are always individual and necessary for optimal 
functioning in life SLE patients. The psychotherapy should help to equip the SLE’s patients, 
that experience significant restrictions into their daily life, with knowledge and skills of 
coping for managing the illness and to build up familiar and social support. The cognitive 
behavioural therapy (coping methods: behavioural change and cognitive models, and 
contextual methods: acceptance and commitment therapy and mindfulness) improves on 
these persons their experience of physical symptom (pain, fatigue,…), daily activity, 
psychology and social functioning.  
7. Key points 
1. The SLE is a chronic inflammatory autoimmune disease of unknown etiology with 
predominance on the female sex in their childbearing years. 
2. The SLE affects heterogeneity multiple organs of the body and presents aberrant 
immunological findings. 
3. The clinical course and prognosis of SLE is unpredictable, it is a disease no cure. 
4. The SLE affect patient’s bio-psycho-social unit. 
5. The integral diagnosis in patients with SLE includes : physical, psychological and social 
aspects.  
6. The treatment of SLE patients should be physical, psychological and social. 
7. The treatment of SLE’s people should be patient-centred. 
8. Healthcare to SLE patients should be multidisciplinary including rheumatologists, 
family physicians, other specialist physicians, psychotherapies, rehabilitations, nurses 
and social workers. 
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9. Medical treatment and a recommended lifestyle are necessary for optimal functioning 
in the life of SLE patients. 
10. The psychotherapy programs should help to equip the SLE’s patients with knowledge 
and skills of coping for managing the illness and to build up familiar and social 
support. 
11. The cognitive behavioural therapy (coping methods and contextual methods) improves 
on the persons’ SLE their experience of physical symptom (pain, fatigue, 
neuropsychiatric manifestations), daily activity, psychology and social functioning. 
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